Lyell Immunopharma (LYEL)

• Market cap: $505M
• 1 day: 3.62%
• 5 days: -3.38%
• 1 month: -27.21%
• 3 months: 39.76%
• 6 months: 149.32%
• Year to date: -18.01%
• 1 year: 112.52%
• 5 years: -92.97%
• 10 years: -92.97%
• Sector: Healthcare
• Industry: Biotechnology

About: Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.

Employees: 300